A phase‐1, open‐label, single‐dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment

nork Csonka, Denes, Hazell, Katharine, Waldron, Edward, Lorenzo, Sebastien, Duval, Vincent, Trandafir, Lucia, Kobalava, Zhanna D.
Argitaratua izan da J Clin Pharmacol (2016)

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

nork Massacesi, Cristian, Di Tomaso, Emmanuelle, Urban, Patrick, Germa, Caroline, Quadt, Cornelia, Trandafir, Lucia, Aimone, Paola, Fretault, Nathalie, Dharan, Bharani, Tavorath, Ranjana, Hirawat, Samit
Argitaratua izan da Onco Targets Ther (2016)

ATNT-12 PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND...

nork Rodon, Jordi, Rosenthal, Mark, Mason, Warren, Segura, Pedro Perez, Beck, Joseph T., Hirte, Holger, DeGroot, John F., Trandafir, Lucia, Pognan, Nathalie, Yang, Lin, Kanwal, Charu, Wen, Patrick Y.
Argitaratua izan da Neuro Oncol (2015)

Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metastases...

nork Sartor, Oliver, Heinrich, Daniel, Mariados, Neil, Méndez Vidal, Maria José, Keizman, Daniel, Thellenberg Karlsson, Camilla, Peer, Avivit, Procopio, Giuseppe, Frank, Stephen J., Pulkkanen, Kalevi, Rosenbaum, Eli, Severi, Stefano, Trigo, José, Trandafir, Lucia, Wagner, Volker, Li, Rui, Nordquist, Luke T.
Argitaratua izan da Prostate (2019)